Aug 9, 2022 · Mutations in the RAS family of proteins promote various cancers, of which mutations at Gln 61 (also referred to as Q61) are relatively and unexpectedly rare in KRAS. Huynh et al. compared the structural, biochemical, and biological effects of Gln 61 mutations in KRAS (see also Sealover and Kortum).

Apr 4, 2024 · His team found that the Q61 mutation is found among only 5% of patients with a KRAS mutation, with the highest frequency in those with pancreatic cancer and cholangiocarcinoma. They also found that pancreatic cancer patients with a Q61 mutation had a poorer outlook than those without the mutation, possibly because there is a co-mutation that ...

Aug 9, 2022 · Q61 mutations in KRAS are infrequent and differ markedly in occurrence. Q61H is the predominant mutant (at 57%), followed by Q61R/L/K (collectively 40%), and Q61P and Q61E are the rarest (2 and 1%, respectively).

KRAS Q61H is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS Q61H as a predictive biomarker, 2 are FDA-approved and 7 have …

Nov 1, 2021 · Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i, and investigate the underlying mechanisms using biophysics, molecular dynamics, and cell-based approaches. Q61H...

Mar 2, 2022 · Here we uncover the requirement of the silent KRASG60G mutation for cells to produce a functional KRAS (Q61K). In the absence of this G60G mutation in KRASQ61K, a cryptic splice donor site is...

Here we uncover the requirement of the silent KRAS G60G mutation for cells to produce a functional KRAS (Q61K). In the absence of this G60G mutation in KRAS Q61K, a cryptic splice donor site is formed, promoting alternative splicing and premature protein termination.

Nov 1, 2021 · Cancer cells bearing distinct KRAS mutations exhibit variable sensitivity to SHP2 inhibitors (SHP2i). Here we show that cells harboring KRAS Q61H are uniquely resistant to SHP2i, and investigate the underlying mechanisms using biophysics, molecular dynamics, and cell-based approaches.

KRAS Q61 mutations represent a heterogeneous subgroup of KRAS mutations. However, the prognostic value and the outcome of different treatment options remain unclear. Here, we present a real-word data analysis of KRAS Q61X mutated patients (pts) with NSCLC to further characterize molecular and clinical characteristics of this subgroup.

Dec 1, 2023 · Hydrogen/deuterium exchange mass spectrometry experiments alongside molecular dynamics simulations reveal differences in solvent accessibility and conformational plasticity across a panel of common...